Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee
The DoD (referred to herein as "the Department", "Department of War" or "DoW") is publishing this notice to announce that the following Federal Advisory Committee meeting of the...
Under Secretary of Defense for Personnel and Readiness (USD(P&R)), Department of Defense (DoD).
ACTION:
Notice of Federal Advisory Committee meeting.
SUMMARY:
The DoD (referred to herein as “the Department”, “Department of War” or “DoW”) is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel (UFBAP) will take place.
DATES:
Open to the public.
Wednesday, September 23rd, 10:00 a.m.-1:00 p.m. (Eastern Standard Time).
ADDRESSES:
The meeting will be held telephonically or via conference call. The phone number for remote access is: 1-667-892-3500 or 1-667-892-3600.
This meeting is held under the provisions of chapter 10 of title 5, United States Code
( printed page 56872)
(U.S.C.) (commonly known as the Federal Advisory Committee Act or FACA) and 41 Code of Federal Regulations (CFR) 102-3.140 and 102-3.150.
Purpose of the Meeting:
The UFBAP will review and comment on recommendations made by the DoW Pharmacy and Therapeutics Committee to the Director, Defense Health Agency regarding the Uniform Formulary.
Agenda
1. 10:00 a.m.-10:10 a.m. Sign In for UFBAP members
2. 10:10 a.m.-10:40 a.m. Welcome and Opening Remarks
a. Welcome, Opening Remarks, and Introduction of UFBAP Members by CAPT Phung Thien Nguyen, ADFO, UFBAP
b. Public Written Comments by CAPT Phung Thien Nguyen, ADFO, UFBAP
c. Opening Remarks by Dr. Pamela Schweitzer, UFBAP Chair
d. Introductory Remarks by Dr. Edward Vonberg, Chief, Formulary Management Branch
3. 10:40 a.m.-11:45 a.m. Scheduled Therapeutic Class Reviews
Meeting Accessibility:
Pursuant to section 1009(a)(1) of title 5, U.S.C. and 41 CFR 102-3.140 through 102-3.165, and subject to the availability of phone lines, the meeting is open to the public.
Written Statements:
Pursuant to 41 CFR 102-3.105(j) and 102-3.140(c), and section 1009(a)(3) of title 5, U.S.C., interested persons or organizations may submit written statements to the UFBAP about its mission and/or the agenda to be addressed in the public meetings. Written statements should be submitted to the UFBAP's ADFO. The ADFO's contact information can be found in the
FOR FURTHER INFORMATION CONTACT
section of this notice. Written comments or statements must be received by the UFBAP's ADFO at least five (5) calendar days prior to a meeting so they may be made available to the UFBAP for its consideration prior to a meeting. Written comments received are releasable to the public. The ADFO will review all submitted written statements and provide copies to UFBAP.
Dated: September 1, 2026.
Stephanie J. Bost,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP
chapter 10 of title 5, United States Code
41 CFR 102-3.140